News

Filter

Current filters:

ZetiaMylan Laboratories

101 to 110 of 97182 results

Medicines Australia welcomes new report on Australian pharma industry

Medicines Australia welcomes new report on Australian pharma industry

10-12-2014

A new report has found that the pharmaceutical and medical technology industries in Australia produce…

AustraliaFinancialMedicines AustraliaPharmaceuticalPharmaceuticals policy

FDA Focus: Life-threatening disease and the benefit-risk of treatment options

FDA Focus: Life-threatening disease and the benefit-risk of treatment options

10-12-2014

In the fifth of a monthly FDA-focused blog published exclusively by The Pharma Letter, Dr Nicola Davies…

ChemistryFDAPharmaceuticalRegulationUSA

Spark Thera in potential $280 million hemophilia B deal with Pfizer

Spark Thera in potential $280 million hemophilia B deal with Pfizer

10-12-2014

US gene therapy start up Spark Therapeutics has entered into a global collaboration with pharma giant…

BiotechnologyHematologyLicensingPfizerSpark TherapeuticsSPK-RPE65USA

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

09-12-2014

US pharma major Eli Lilly and partner Incyte Corp today revealed that the Phase III RA-BEACON study of…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteResearchUSA

Zydus launches world’s first biosimilar of Humira

Zydus launches world’s first biosimilar of Humira

09-12-2014

A biosimilar of AbbVie’s blockbuster drug Humira (adalimumab) has been launched in India by generic…

AbbVieAnti-Arthritics/RheumaticsBiosimilarsHumiraIndiaMarkets & MarketingZydus Cadila

ASH 2014: Gilead announces good response rates for Zydelig in non-Hodgkin lymphoma

ASH 2014: Gilead announces good response rates for Zydelig in non-Hodgkin lymphoma

09-12-2014

US biotech major Gilead Sciences has announced long-term follow-up results from the registration studies…

Gilead SciencesOncologyPharmaceuticalResearchUSAZydelig

Bayer collaborates with DNDi on novel, oral human river blindness treatment

09-12-2014

German pharma major Bayer and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement…

Astellas PharmaBayeremodepsidePharmaceuticalResearchTropical diseases

Calithera gains exclusive, global license to Mars Symbioscience's arginase inhibitors

09-12-2014

Calithera Biosciences has signed an exclusive global license agreement with Mars Symbioscience, a division…

BiotechnologyCalithera BiosciencesGlobalLicensingMars SymbioscienceOncology

101 to 110 of 97182 results

Back to top